Filana Therapeutics, Inc. (FLNA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Filana Therapeutics, Inc. (FLNA) closed at USD 0.73 on 2026-10-14, a change of -79.6 % over the past year, with a market capitalization of USD 36.75M.

Filana Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Filana Therapeutics, Inc. key figures

Previous close

USD 0.73 (2026-10-14)

1-year change

-79.6 %

Market cap

USD 36.75M

Enterprise value

USD -45.93M

P/E ratio (trailing)

-0.87

P/E ratio (forward)

n/a

EPS (trailing)

-0.87

EPS (forward)

n/a

PEG ratio

1.62

Price to book

0.58

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.16

Employees

17

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Filana Therapeutics, Inc.

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Filana Therapeutics, Inc. and compare it with other stocks.